Shots: The P-II/III study evaluates opaganib +SoC vs PBO + SoC in a ratio (1:1) in 475 patients with COVID-19 pneumonia requiring hospitalization & treatment with supplemental oxygen The preliminary […]readmore
Tags : Opaganib
Shots: RedHill has submitted CTA to the MHRA and AIFA for a P-II/III study evaluating opaganib vs PBO along with SOC in patients hospitalized with severe COVID-19. The P-II/III study […]readmore
Shots: RedHill has submitted CTA with the Ministry of Health of the Russian Federation for a P-II/III clinical study evaluating Yeliva (opaganib, ABC294640)1 in patients hospitalized with severe COVID-19 and […]readmore